Gene
HIF1A
HIF1A is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (81), Actionable biomarkers (1), Trial mentions (9), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention HIF1A. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 22 at the structurally incomplete recent edge.
HIF1A has 9 trial mentions across 7 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 96 of 11,460 | 0.84% |
| 2022 | 0 of 8,285 | 0.00% | 133 of 13,598 | 0.98% |
| 2021 | 0 of 8,692 | 0.00% | 163 of 15,045 | 1.08% |
| 2020 | 0 of 7,640 | 0.00% | 141 of 14,459 | 0.98% |
| 2019 | 0 of 7,300 | 0.00% | 118 of 12,159 | 0.97% |
| 2018 | 0 of 6,927 | 0.00% | 96 of 11,854 | 0.81% |
| 2017 | 0 of 6,558 | 0.00% | 99 of 11,595 | 0.85% |
Showing 10 of 37 years.
Assay-provider ledger (81)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Bioassay Technology Laboratory | Reagent supplier | Clinical validation | 2 | July 11, 2026 |
| ELK Biotechnology | Reagent supplier | Clinical validation | 2 | July 11, 2026 |
| AB Applied Biosystems | Reagent supplier | Clinical validationAnalytical validation | 5 | January 21, 2026 +1 undated |
| BIO-RAD | Reagent supplier | Clinical validation | 1 | January 21, 2026 |
| GraphPad Software | Reagent supplier | Clinical validation | 1 | January 21, 2026 |
Showing 5 of 81 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| HIF1A overexpression | SUNITINIB | response-associated | renal carcinoma | Cancer Genome Interpreter |
Trial mentions (9)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01814449 | Trial biospecimen (AACT) |
| NCT00117013 | Trial eligibility (AACT) |
| NCT01075399 | Trial eligibility (AACT) |
| NCT06048614 | Trial eligibility (AACT) |
| NCT02192541 | Trial outcomes (AACT) |
Showing 5 of 9 trial mentions.
Target-disease associations (758)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Aarskog-Scott syndrome, X-linked | genetic, familial or congenital disease | Literature (Europe PMC) |
| Abdominal Aortic Aneurysm | cardiovascular disease | Literature (Europe PMC) |
| Abnormal intestine morphology | phenotype | Literature (Europe PMC) |
Showing 5 of 758 associations.
Vendor sourcing (30)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The HIF1A c.746A>C; p.Asp249Ala variant (rs373399672), to our knowledge, is not reported in the medical literature or gene specific databases in the context ... | View ClinVar record SCV007330492.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1091T>C (p.V364A) alteration is located in exon 9 (coding exon 9) of the HIF1A gene. This alteration results from a T to C substitution at nucleotide p... | View ClinVar record SCV003530344.2 |
| Children's Hospital of Philadelphia | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV000257895.2 |
| Duke-NUS Graduate Medical School | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Criteria A: For infant presenting with early onset of MOP 1. Birth weight 500 - 1250 gram 2. ≥ 23 weeks gestation 3. No BO for 48 hours 4. BO p... | View trial NCT06048614 |
| Duke-NUS Graduate Medical School | Trial collaborator | Mentioned in trial textTrial free-text mention | MOP1 | View trial NCT06048614 |
Showing 5 of 30 sourcing records.
Trial-cited literature (1,704)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: An open-label randomized pilot study. | Journal of clinical anesthesia | 2025 | 27 |
| Pathophysiological Markers of Acute Respiratory Distress Syndrome Severity Are Correlated With Ventilation-Perfusion Mismatch Measured by Electrical Impedance Tomography. | Critical care medicine | 2025 | 8 |
| Effects of blood flow restriction combined with high-load training on muscle strength and sports performance in athletes: a systematic review and meta-analysis. | Frontiers in physiology | 2025 | 7 |
| Impact of sleep deprivation on colon cancer: Unraveling the KynA-P4HA2-HIF-1α axis in tumor lipid metabolism and metastasis. | Molecular metabolism | 2025 | 6 |
| Neurophysiological Effects of Dry Needling: A Systematic Review and Meta-analysis. | Archives of physical medicine and rehabilitation | 2025 | 5 |
Showing 5 of 1,704 papers.
Protein variant mentions (17)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A12R | 1 | 2023 | PMID 36171460 |
| p.A588T | 5 | 2010 to 2023 | PMID 36675214, PMID 34708297, PMID 32201506 |
| p.C13Q | 1 | 2021 | PMID 33473210 |
| p.D422Y | 1 | 2015 | PMID 25741868 |
| p.G1790A | 1 | 2016 | PMID 27593081 |
Showing 5 of 17 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.K391R | TCGA-THCA | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Squamous Cell Neoplasms; Thyroid gland | 1 | 507 | 0.20% | 0.03% to 1.11% |
| p.R30Q | TCGA-SKCM | Nevi and Melanomas; Skin; Connective, subcutaneous and other soft tissues; Lymph nodes; Nasal cavity and middle ear; Vulva; Breast; Bones, joints and articular cartilage of other and unspecified sites; Retroperitoneum and peritoneum; Vagina; Colon; Adrenal gland; Corpus uteri; Other and ill-defined sites; Liver and intrahepatic bile ducts; Anus and anal canal; Spinal cord, cranial nerves, and other parts of central nervous system; Small intestine; Bronchus and lung; Brain; Parotid gland | 1 | 470 | 0.21% | 0.04% to 1.20% |
Literature-extracted relations (464)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Anhydrous glucose | Chemical | associate |
CDH1 Orchestrates Anabolic Events to Promote Cell Cycle Initiation. | 2025 |
| Oxygen | Chemical | positive_correlate |
Regulation of hypoxia-inducible factor 1α by optimal oxygen concentration enhances oocyte maturation and early embryonic development in buffalo. | 2023 |
| Nitroglycerin | Chemical | negative_correlate |
Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial. | 2023 |
| Oxygen | Chemical | associate |
The Role of Hypoxia-Inducible Factor-1 Alpha in Renal Disease. | 2022 |
| Anhydrous glucose | Chemical | associate |
Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. | 2022 |
Showing 5 of 464 relation assertions.
Organizations publishing (885)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 50 | 2002 to 2023 |
| Harvard Medical School | Academic | 40 | 1998 to 2023 |
| Mass General Brigham | Hospital | 34 | 2004 to 2024 |
| The University of Texas System | Academic | 34 | 2004 to 2023 |
| University of London | Academic | 26 | 2007 to 2024 |
Showing 5 of 885 organizations.
Where HIF1A appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
705 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.